Prospective analysis of clinical and cytogenetic features of 435 cases of MDS diagnosed using the WHO (2001) classification: A prognostic scoring system for predicting survival in RCMD

International Journal of Hematology

Volumn 90, Issue 3, 2009, Pages 361-369

  Wang, Xiao Qin ^a,b   Ryder, John ^c   Gross, Sherilyn A ^a,d   Lin, Guowei ^b   Irons, Richard D ^a,b,d,e,f,g  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e Cinpathogen Inc   (United States)

^f Cinpathogen Inc   (China)

^g Fudan Cinpathogen Clinical and Molecular Research Center   (China)

Author keywords

IPSS; Myelodysplastic syndrome; Overall survival; WHO classification; WPSS

Indexed keywords

ACLARUBICIN; CYCLOSPORIN A; CYTARABINE; DAUNORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; HOMOHARRINGTONINE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CLINICAL FEATURE; CYTOGENETICS; DISEASE CLASSIFICATION; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; INTERNATIONAL PROGNOSIS SCORING SYSTEM; KARYOTYPE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREVALENCE; PROGNOSIS; SCORING SYSTEM; SURVIVAL TIME; WHO CLASSIFICATION BASED PROGNOSTIC SCORING SYSTEM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; CHROMOSOME ABERRATIONS; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROMES; PREDICTIVE VALUE OF TESTS; PREVALENCE; PROGNOSIS; RISK FACTORS; WORLD HEALTH ORGANIZATION; YOUNG ADULT;

EID: 76449088519     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-009-0403-5     Document Type: Article

References (16)

1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissue. Lyon: IARC; 2008.
2. Jaffe E, Harris N, Stein H, Vardiman J. World Health Organization classification of tumours. pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001.
3. U Germing N Gattermann C Strupp M Aivado C Aul 2000 Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients Leuk Res 24 983 992 10.1016/S0145- 2126(00)00088-6 1:STN:280:DC%2BD3M%2FltVyhug%3D%3D 11077111 (Pubitemid 30833152)
4. P Greenberg C Cox MM LeBeau P Fenaux P Morel G Sanz, et al. 1997 International scoring system for evaluating prognosis in myelodysplastic syndromes Blood 89 2079 2088 1:CAS:528:DyaK2sXhvVars70%3D 9058730
5. L Malcovati U Germing A Kuendgen MG Della Porta C Pascutto R Invernizzi, et al. 2007 Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes J Clin Oncol 25 3503 3510 10.1200/JCO.2006.08.5696 17687155 (Pubitemid 47315575)
6. WR Sperr F Wimazal M Kundi C Fonatsch R Thalhammer-Scherrer GH Schernthaner, et al. 2001 Survival analysis and AML development in patients with de novo myelodysplastic syndromes: comparison of six different prognostic scoring systems Ann Hematol 80 272 277 10.1007/s002770000280 1:STN:280:DC%2BD3Mzpt1eksA%3D%3D 11446729 (Pubitemid 32515048)
7. H Muller-Berndorff PS Haas R Kunzmann J Schulte-Monting M Lubbert 2006 Comparison of five prognostic scoring systems, the French-American-British (FAB) and World Health Organization (WHO) classifications in patients with myelodysplastic syndromes: results of a single-center analysis Ann Hematol 85 502 513 10.1007/s00277-005-0030-z 1:STN:280:DC%2BD28rgs1amsQ%3D%3D 16715299 (Pubitemid 44283093)
8. A Matsuda U Germing I Jinnai M Misumi A Kuendgen S Knipp, et al. 2005 Difference in clinical features between Japanese and German patients with refractory anemia in myelodysplastic syndromes Blood 106 2633 2640 10.1182/blood-2005-01-0040 1:CAS:528:DC%2BD2MXhtFantbvE 15972453 (Pubitemid 41510734)
9. A Kuendgen A Matsuda U Germing 2007 Differences in epidemiology of MDS between western and eastern countries: Ethnic differences or environmental influence? Leuk Res 31 103 104 10.1016/j.leukres.2006.03.007 16630658 (Pubitemid 44709743)
10. B Chen WL Zhao J Jin YQ Xue X Cheng XT Chen, et al. 2005 Clinical and cytogenetic features of 508 Chinese patients with myelodysplastic syndrome and comparison with those in Western countries Leukemia 19 767 775 10.1038/sj.leu.2403688 1:CAS:528:DC%2BD2MXjsFOkt7c%3D 15759035 (Pubitemid 40663096)
11. RD Irons X Wang SA Gross L Bao J Ryder Y Chen, et al. 2006 Prevalence of MDS subtypes in Shanghai, China: a comparison of the World Health Organization and French American British classifications Leuk Res 30 769 775 10.1016/j.leukres.2005.10.018 16337268 (Pubitemid 43816690)
12. X Ma M Does A Raza ST Mayne 2007 Myelodysplastic syndromes: incidence and survival in the United States Cancer 109 1536 1542 10.1002/cncr.22570 17345612 (Pubitemid 46595689)
13. M Breccia M Mancini M Nanni GM D'Elia I Carmosino R Latagliata, et al. 2005 Clinical features of prognostic significance in myelodysplastic patients with normal karyotype at high risk of transformation Leuk Res 29 33 39 10.1016/j.leukres.2004.05.010 15541472 (Pubitemid 39487906)
14. C Aul N Gattermann A Heyll U Germing G Derigs W Schneider 1992 Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system Leukemia 6 52 59 1:STN:280: DyaK387jvF2gtA%3D%3D 1736014
15. G Garcia-Manero J Shan S Faderl J Cortes F Ravandi G Borthakur, et al. 2008 A prognostic score for patients with lower risk myelodysplastic syndrome Leukemia 22 538 543 10.1038/sj.leu.2405070 1:STN:280:DC%2BD1c7nsVKntw%3D%3D 18079733
16. H Kantarjian JP Issa CS Rosenfeld JM Bennett M Albitar J DiPersio, et al. 2006 Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study Cancer 106 1794 1803 10.1002/cncr.21792 1:CAS:528:DC%2BD28XksFCrsrk%3D 16532500